Altay Therapeutics raises $37 million in Series A with Fountain Healthcare Partners participation
Altay Therapeutics closed a $37 million Series A financing with participation from Fountain Healthcare Partners. Sound Bioventures and HealthCap co-led the round. * Altay develops small-molecule inhibitors of transcription factors; its lead candidate, oral DUX4 inhibitor DX5057, targets facioscapulohumeral muscular dys